ArticleEClinicalMedicine2025

Safety, tolerability and clinical effects of rovunaptabin, also known as BC007 on fatigue and quality of life in patients with Post-COVID syndrome (reCOVer): a prospective, exploratory, placebo-controlled, double-blind, randomised phase IIa clinical trial (RCT).

Bettina Hohberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.